paroxetine + pindolol

Paroxetine + pindolol is a combination of two small molecule drugs used primarily in psychiatric research and clinical practice to accelerate and augment the antidepressant response in major depressive disorder and potentially anxiety disorders. Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by inhibiting its reuptake, while pindolol is a non-selective beta-adrenergic blocker with additional antagonistic activity at the presynaptic serotonin 1A (5-HT1A) receptor. The rationale for combining these agents lies in the ability of pindolol to block 5-HT1A autoreceptors, which may otherwise delay or limit the full antidepressant effect of SSRIs like paroxetine. This combination has been shown to accelerate onset of antidepressant action, enhance panicolytic effects, and alter sleep architecture by increasing REM suppression compared to either drug alone[1][2][5]. It has been studied both in healthy volunteers and patients with depression or panic disorder.